Literature DB >> 8039921

Association between transcript levels of the Pseudomonas aeruginosa regA, regB, and toxA genes in sputa of cystic fibrosis patients.

T L Raivio1, E E Ujack, H R Rabin, D G Storey.   

Abstract

In this study, we examined the regulation of exotoxin A (ETA) production by Pseudomonas aeruginosa during chronic lung infections of cystic fibrosis (CF) patients. We used a recently developed technique termed population transcript accumulation in hybridization studies with RNA extracted from sputa. With this technique, we demonstrated that the structural gene for ETA, toxA, as well as two genes encoding positive regulators of ETA synthesis, regA and regB, were expressed in the lungs of CF patients infected with P. aeruginosa. These genes were always expressed together, never alone or in pairs, suggesting coincident expression and a possible regulatory role for regA and regB in this environment. Fluctuations in the levels of the three gene products were observed among samples, consistent with a regulatory phenomenon. The level of regB RNA detected never exceeded that of regA, although the ratio of regA RNA to regB RNA detected did change between samples. These observations are in agreement with in vitro observations which have shown that regB is located 3' to regA in an operon which is expressed from two independently regulated promoters located upstream of regA. The presence of high levels of toxA, regA, and regB RNAs in some sputum samples prompted us to look for hyperproducing-toxin strains in the sputa of CF patients. In vitro, one such strain, 4384, had a transcript accumulation pattern for toxA, regA, and regB similar to that of a laboratory hyperproducer of ETA, strain PA103. These observations suggest that regA and regB are involved in the regulation of ETA production in strains of P. aeruginosa infecting the lungs of CF patients and that some of these strains may regulate ETA production in a manner similar to that of the hyperproducing-ETA strain PA103.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8039921      PMCID: PMC302984          DOI: 10.1128/iai.62.8.3506-3514.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.609


  48 in total

1.  Toxin inhibitors of protein synthesis: production, purification, and assay of Pseudomonas aeruginosa toxin A.

Authors:  B H Iglewski; J C Sadoff
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

2.  Heterogeneity, persistence, and distribution of Pseudomonas aeruginosa genotypes in cystic fibrosis patients.

Authors:  M Fegan; P Francis; A C Hayward; J A Fuerst
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

3.  Kinetics of toxA and regA mRNA accumulation in Pseudomonas aeruginosa.

Authors:  D W Frank; B H Iglewski
Journal:  J Bacteriol       Date:  1988-10       Impact factor: 3.490

4.  Exotoxins of Pseudomonas aeruginosa. I. Factors that influence the production of exotoxin A.

Authors:  P V Liu
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

5.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

6.  Relative ion permeability of normal and cystic fibrosis nasal epithelium.

Authors:  M Knowles; J Gatzy; R Boucher
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

7.  Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis.

Authors:  G Döring; N Høiby
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

8.  Identification of the cystic fibrosis gene: chromosome walking and jumping.

Authors:  J M Rommens; M C Iannuzzi; B Kerem; M L Drumm; G Melmer; M Dean; R Rozmahel; J L Cole; D Kennedy; N Hidaka
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

9.  Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis.

Authors:  A E Hollsing; M Granström; M L Vasil; B Wretlind; B Strandvik
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 11.677

10.  The superantigen Pseudomonas exotoxin A requires additional functions from accessory cells for T lymphocyte proliferation.

Authors:  P K Legaard; R D LeGrand; M L Misfeldt
Journal:  Cell Immunol       Date:  1991-07       Impact factor: 4.178

View more
  4 in total

1.  Pseudomonas aeruginosa cystic fibrosis isolates from individual patients demonstrate a range of levels of lethality in two Drosophila melanogaster infection models.

Authors:  Erika I Lutter; Monica M P Faria; Harvey R Rabin; Douglas G Storey
Journal:  Infect Immun       Date:  2008-02-19       Impact factor: 3.441

2.  Positive correlation of algD transcription to lasB and lasA transcription by populations of Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis.

Authors:  D G Storey; E E Ujack; I Mitchell; H R Rabin
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.609

3.  Pseudomonas aeruginosa lasR transcription correlates with the transcription of lasA, lasB, and toxA in chronic lung infections associated with cystic fibrosis.

Authors:  D G Storey; E E Ujack; H R Rabin; I Mitchell
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.609

4.  Genomic heterogeneity underlies multidrug resistance in Pseudomonas aeruginosa: A population-level analysis beyond susceptibility testing.

Authors:  Laura J Rojas; Mohamad Yasmin; Jacquelynn Benjamino; Steven M Marshall; Kailynn J DeRonde; Nikhil P Krishnan; Federico Perez; Andrew A Colin; Monica Cardenas; Octavio Martinez; Armando Pérez-Cardona; Daniel D Rhoads; Michael R Jacobs; John J LiPuma; Michael W Konstan; Alejandro J Vila; Andrea Smania; Andrew R Mack; Jacob G Scott; Mark D Adams; Lilian M Abbo; Robert A Bonomo
Journal:  PLoS One       Date:  2022-03-31       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.